Shots:

• Regeneron pauses dosing of the garetosmab (REGN2477) in the ongoing P-II LUMINA-1 study in patients with FOP. The pause is due to fatal serious AEs in the study during the open-label extension during which all patients received active treatment
• Regeneron shared the update with the trial’s IDMC and regulatory authorities and will conduct a review of the study to better understand the benefit/risk profile of garetosmab in people with FOP
• Garetosmab is a VelocImmune-derived mAb that binds and neutralizes Activin A- which is involved in the development of heterotopic bone in people with FOP

  Ref: Regeneron | Image: The Print